Deuterated cyclosporine analogs and their use as immunomodulating agents

a cyclosporine analog and immunomodulating agent technology, applied in the field of cyclosporin derivatives, can solve the problem of not doing anything to modify the immunologic basis

Inactive Publication Date: 2002-09-19
NAICKER SALVARAJ +2
View PDF0 Cites 61 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0052] Substitution and deuteration of the cyclosporine molecule results in altered physicochemical and pharmacokinetic properties which enhance its usefulness in the treatment of transplantation rejection, host vs. graft disease, graft vs. host disease, aplastic anemia, focal and segmental glomeruloscierosis, myasthenia gravis, psoriatic arthritis, relapsing polychondritis and ulcerative colitis.

Problems solved by technology

Anti-inflammatory agents, such as NSAID's (Non-Steroidal Anti-inflammatory Drugs), and corticosteroids act principally by blocking the effect of, or secretion of, these mediators, but do nothing to modify the immunologic basis of the disease.
However, it is nephrotoxic and is known to cause the following undesirable side effects:

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Deuterated cyclosporine analogs and their use as immunomodulating agents
  • Deuterated cyclosporine analogs and their use as immunomodulating agents
  • Deuterated cyclosporine analogs and their use as immunomodulating agents

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0073] To a stirred solution of cyclosporine 1(1.01 g, 0.84 mmol) in acetic anhydride (20 mL) at room temperature was added DMAP (150 mg, 1.23 mmol 1.5 eq). After stirring overnight, the reaction mixture was partitioned between EtOAc (50 ml) and water (25 ml). The separated EtOAc layer was then washed with water (50 mL) and brine (50 mL), dried (MgSO.sub.4) and the solvent removed in vacuo to give the crude product as a glassy solid. Purification by flash chromatography through a short column of silica (2% MeOH / DCM) and lyophilisation from benzene yielded 2 (1.044 g, 0.84 mmol, quant.) as a fluffy, colourless solid; [.alpha.].sub.D.sup.25-305.7 (c. 0.3, CHCl.sub.3); .nu..sub.max (CHCl.sub.3 cast) / cm.sup.-1 3328m, 2963m, 1746m, 1627s, 1528m, 1472m, 1233m; .delta..sub.H (600 MHz, C.sub.6D.sub.6) 8 73 (1H, d, J=9.5 Hz, NH, 8.30 (1H, d, J=7.0 Hz, NH), 7.92 (1H, d, J=7.5 Hz, NH), 7.49 (1H, d, J=7.5 Hz, NH), 6.05 (1H, d, J=11.5 Hz), 5.88 (1H, dd, J=3.5, 11.5 Hz), 5.82 (1H, d, J=11.5 Hz), ...

example 2

[0074] To a solution of compound 2 (289 mg, 0.23 mmol) in a 1:1 mixture of dioxane and water (5 mL) was added firstly sodium metaperiodate (100 mg, 0.47 mmol, 2 eq) and secondly a solution of osmium tetraoxide (5 mL; 0.5 g OsO.sub.4 in 250 mL of solvent). Two-phase work-up, purification by flash column chromatography (40% acetone in petroleum ether) and lyophilisation from benzene gave compound 3. (226 mg, 0.18 mmol, 80%) as a fluffy, colourless solid; [.alpha.].sub.D.sup.25-260.0 (c. 0.1, CHCl.sub.3); .nu..sub.max (CHCl.sub.3 cast) / cm.sup.-1 3325m, 2962m, 1748w, 1724w, 1677m, 1626s, 1228m, 755m; .delta..sub.H (300 MHz, C.sub.6D.sub.6) 8.63 (1H, d, J=9.5 Hz, NH), 8.16 (1H, d, J=7.0 Hz, NH), 7.95 (1H, d, J=7.5 Hz, NH) 7.48 (1H, d, J=9.0 Hz, NH), 5.93 (1H, d, J=7.5 Hz), 5.84 (1H, dd, J=4.0, 11.5 Hz), 5.70 (1H, d, J=11.5 Hz). 5.56-5.54 (1H, m), 5.32 (1H, dd, J=5.5, 8.0 Hz), 5.07-4.88(3H, complex), 4.72 (1H, p, J=7.0 Hz), 4.49 (1H, p, J=7.0 Hz), 3.98 (1H, d, J=14.0 Hz), 3.42 (3H, s, CH....

example 3

[0075] Method A: To a solution of compound 3(315 mg, 0.26 mmol) in THF (5 mL) at 0.degree. C. was added a solution of the deutero-phosphorus ylid (2.67 mmol, .about.10 eq), prepared from d.sub.5-ethyltriphenylphosphoniu-m iodide. After work-up, purification by flash column chromatography (30% to 60% acetone in PE) and HPLC (60% to 65% MeCN in water), then lyophilisation from benzene yielded compound 4 (153 mg, 0.12 mmol, 47%) as a fluffy, colourless solid.

[0076] Method B: To a stirred solution of compound 3 (287 mg, 0.23 mmol) in THF (5 mL) under Ar at -78.degree. C. was carefully added a solution of phosphorus ylid (formed by the addition of sodium hexamethyldisilylamide (1.0M; 2.25 mL, 2.25 mmol, .about.10 eq) to a suspension of d.sub.5-ethyltriphenylphosphonium iodide (480 mg, 1.13 mmol, .about.5 eq) in THF (10 mL) under Ar at room temperature). After stirring for 2 hr with gradual warming to room temperature, the reaction mixture was cooled to 0.degree. C. and was quenched by th...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
radiusaaaaaaaaaa
temperatureaaaaaaaaaa
body weightaaaaaaaaaa
Login to view more

Abstract

Cyclosporine derivatives are disclosed which possess enhanced efficacy and reduced toxicity over naturally occurring and other presently known cyclosporins and cyclosporine derivatives. The cyclosporine derivatives of the present invention are produced by chemical and isotopic substitution of the cyclosporine A (CsA) molecule by: (1) Chemical substitution and optionally deuterium substitution of amino acid 1; and (2) deuterium substitution at key sites of metabolism of the cyclosporine A molecule such as amino acids 1, 4, 9. Also disclosed are methods of producing the cyclosporine derivatives and method of producing immunosuppression with reduced toxicity with the disclosed cyclosporine derivatives.

Description

INTRODUCTION AND BACKGROUND[0001] Cyclosporin derivatives of the present invention are disclosed which possess enhanced efficacy and reduced toxicity over naturally occurring and other presently known cyclosporins and cyclosporine derivatives. The cyclosporin derivatives of the present invention are produced by chemical and isotopic substitution of the cyclosporine A (CsA) molecule by:[0002] 1. Chemical substitution and optionally deuterium substitution of amino acid 1; and[0003] 2. Deuterium substitution at key sites of metabolism of the cyclosporine A molecule such as amino acids 1, 4, 9.[0004] The cyclosporins are a family of, neutral, hydrophobic cyclic undecapeptides, containing a novel nine-carbon amino acid (MeBmt) at position 1 of the ring that exhibit potent immunosuppressive, antiparasitic, fungicidal, and chronic anti-inflammatory properties. The naturally occurring members of this family of structurally related compounds are produced by various fungi imperfecti. Cyclospo...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(United States)
IPC IPC(8): A61P1/04A61P7/06A61P13/12A61P17/06A61P19/02A61P19/08A61K38/00A61P21/04A61P37/02A61P37/06A61P41/00C07B59/00C07K1/107C07K1/12C07K1/13C07K7/06C07K7/64
CPCA61K38/00C07B59/008C07K1/13C07K7/64C07K7/645Y10S530/806Y10S530/807A61P1/04A61P13/12A61P17/06A61P19/00A61P19/02A61P19/08A61P21/04A61P25/00A61P29/00A61P37/00A61P37/02A61P37/06A61P41/00A61P7/06
Inventor NAICKER, SALVARAJYATSCOFF, RANDALL W.FOSTER, ROBERT T.
Owner NAICKER SALVARAJ
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap